Sipuleucel-T is produced by ex vivo activation of patient-derived peripheral blood mononuclear cells by incubation with a fusion protein, PA2024, comprised of granulocyte-macrophage colony-stimulating factor (GM-CSF) and prostatic acid phosphatase, which is expressed on over 95% of prostate cancers [3]. The gene discussed is CSF2; the disease is prostate carcinoma.